Navigation Links
Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment
Date:8/17/2008

SYDNEY, Australia, Aug. 17 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the first pivotal Phase 3 clinical trial of Bronchitol for the treatment of cystic fibrosis has completed enrolment.

The first efficacy data from the trial is expected to be available during the first half of 2009. The trial commenced its dosing phase in April 2007, reached its initial recruitment target of 250 subjects in June 2008 and closed today with 325 subjects enrolled. Recruitment was extended to cater for a lower numbers of patients than anticipated entering the study on rhDNASE.

The trial is a double blind, comparator controlled, randomised study comparing 400 mg of Bronchitol twice a day to control. The trial includes a 26-week efficacy and safety component, followed by a 26 week open-label Bronchitol safety extension.

The primary efficacy end-point is change from baseline in FEV1 (forced expiratory volume in one second) after 26 weeks.

Pharmaxis Chief Executive Officer Alan Robertson said: "It is rewarding to reach this milestone in bringing Bronchitol to the marketplace. The study has enrolled well, and we look forward to the results helping to shape cystic fibrosis clinical practice in the future."

Pharmaxis has received Orphan Drug Designation and fast track status from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency for Bronchitol in cystic fibrosis.

Bronchitol is designed to hydrate the airway surface of the lungs, improve lung hygiene and promote normal lung clearance.

Approximately 75,000 people in the major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.

To find out more about Pharmaxis, go to http://www.pharmaxis.com.au .

Forward-Looking Statements

The statements contained in thi
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bronchitol Cystic Fibrosis Dose Trial Results Positive
2. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
3. Pharmaxis Establishes Named Patient Program for Bronchitol
4. Pharmaxis Long-Term Safety Study of Bronchitol Completes
5. Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
6. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
7. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
8. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
9. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 Research and Markets ( ... "Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - ... At present, the global market for urinary catheters ...
(Date:1/23/2015)... 2015 More than a third of reproductive-aged women enrolled ... private insurance, filled a prescription for an opioid pain medication ... week,s Morbidity and Mortality Weekly Report (MMWR). ... moderate to severe pain.  They are also found in some ...
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
Breaking Medicine Technology:Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... plc (LSE: SHP, NASDAQ: SHPGY ), the ... approval status and availability of ProAmatine® (midodrine HCl), a ... (SOH).  Shire has engaged in consistent dialogue with the ... 12 months in the hopes of either securing final ...
... YORK, Sept. 22, 2011 Big ideas are coming out ... world is noticing. The Economist Intelligence Unit says for a ... of patents per person. "New Zealanders are ... existing technologies in groundbreaking ways that push the envelope," says ...
Cached Medicine Technology:Shire Provides Update on ProAmatine® (midodrine HCl) 2Shire Provides Update on ProAmatine® (midodrine HCl) 3Shire Provides Update on ProAmatine® (midodrine HCl) 4Cool New Zealand Inventions 2Cool New Zealand Inventions 3
(Date:1/22/2015)... January 23, 2015 The U.S. Pharmacopeial ... DICVP, Director of Clinical Pharmacy Services at North Carolina ... recipient of the 2015 Beal Award for Distinguished Volunteer ... has relied on the contributions of volunteer experts to ...
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... the gene expression of their lungs similar to that suffered ... This is the conclusion of a new study, led by ... in causing these alterations. "Our objective was to analyse ... tissue samples of patients with COPD, whether smokers or not, ...
... carried out in Valencia shows that 37.4% of children aged from 6 ... of those aged from 12 to 15 wake up feeling refreshed only ... that 4.26% of them fall asleep in class more than three times ... we sleep throughout our lives depends on how we learn to sleep ...
... before a patient is diagnosed with SLE. This is because ... diseases. However, with this blood-based test, it is possible to ... Christer Wingren, associate professor in Immunotechnology at CREATE Health, Lund ... disease has progressed. There are three different variants of SLE, ...
... colonoscopy is an invaluable procedure for detecting problems in ... issues and even catch the warning signs of colorectal ... takes practice. But just how much practice makes perfect? ... and his Mayo Clinic research team set out to ...
... study of the human form of mad cow disease failed ... Coroners, Society of England and Wales (CSEW) did not recognise ... risks associated with variant Creutzfeldt-Jakob disease (vCJD) when it decided ... is the conclusion of a paper co-written by a researcher ...
... -- People at risk for celiac disease ought to be ... a new study suggests. Celiac disease is a disorder ... person consumes gluten, a protein found in wheat, rye and ... grown rapidly in recent decades, but, according to the study ...
Cached Medicine News:Health News:Smokers undergo the same changes in gene expression as patients with COPD 2Health News:One-third of Spanish children do not wake up feeling refreshed 2Health News:New test could give SLE patients a more tolerable life 2Health News:Mayo Clinic studies how much practice makes perfect when performing colonoscopies 2Health News:Coroners wrong to say no to post-mortem tissue collection, academics argue 2Health News:More People May Benefit From Going Gluten-Free 2
... Repair System is an evolutionary product for ... Although initially designed specifically for use with ... is quickly becoming a new standard for ... system includes a unique method to deliver ...
... Tunnel Release System is a technological breakthrough ... using a minimally-invasive approach, provides significant patient ... base of the wrist,creates an entry for ... to a standard video camera system, provides ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
... orifice tip, the Finntip Wide is designed ... macromolecules like genomic DNA. This tip eliminates ... It is excellent for use with extremely ... inside diameter of the orifice is 1.1 ...
Medicine Products: